FDA Authorizes QuickVue At-Home COVID-19 Test

QuickVue At-Home COVID-19 Test for symptomatic people suspected of COVID-19. Available with a prescription from a heath care provider

If your email program has trouble displaying this email, view as a webpage. COVID-19 Update: FDA Issues Authorization for the Quidel QuickVue At-Home COVID-19 Test   Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to Quidel for its QuickVue At-Home COVID-19 Test for at-home use with a prescription. The Quidel QuickVue At-Home COVID-19 Test: Is an antigen test that detects proteins from SARS-CoV-2, the virus that causes COVID-19, from a nasal swab sample. Gives a result in 10-15 minutes without needing to send a sample to a laboratory for analysis. The Quidel QuickVue At-Home COVID-19 Test is authorized for: Prescription use within the first six days of onset of COVID-19 symptoms. At-home use with a self-collected nasal swab sample by people age 14 years and older or people age 8 years and older when the nasal swab sample is collected by an adult. Read More Questions? If you have questions, contact the Division of Industry and Consumer Education.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA